scholarly journals Equivalence of solutions between the four-dimensional novel and regularized EGB theories in a cylindrically symmetric spacetime

2020 ◽  
Vol 80 (11) ◽  
Author(s):  
Zi-Chao Lin ◽  
Ke Yang ◽  
Shao-Wen Wei ◽  
Yong-Qiang Wang ◽  
Yu-Xiao Liu

AbstractRecently, a novel four-dimensional Einstein–Gauss–Bonnet (EGB) theory was presented to bypass the Lovelock’s theorem and to give nontrivial effects on the four-dimensional local gravity. The main mechanism is to introduce a redefinition $$\alpha \rightarrow \alpha /(D-4)$$ α → α / ( D - 4 ) and to take the limit $$D\rightarrow 4$$ D → 4 . However, this theory does not have standard four-dimensional field equations. Some regularization procedures are then proposed to address this problem (http://arxiv.org/abs/2003.11552, http://arxiv.org/abs/2003.12771, http://arxiv.org/abs/2004.08362, http://arxiv.org/abs/2004.09472, http://arxiv.org/abs/2004.10716). The resultant regularized four-dimensional EGB theory has the same on-shell action as the original theory. Thus it is expected that the novel four-dimensional EGB theory is equivalent to its regularized version. However, the equivalence of these two theories is symmetry-dependent. In this paper, we test the equivalence in a cylindrically symmetric spacetime. The well-defined field equations of the two theories are obtained, with which our follow-up analysis shows that they are equivalent in such spacetime. Cylindrical cosmic strings are then considered as specific examples of the metric. Three sets of solutions are obtained and the corresponding string mass densities are evaluated. The results reveal how the Gauss–Bonnet term in four dimensions contributes to the string geometry in the new theory.

2015 ◽  
Vol 30 (37) ◽  
pp. 1550202 ◽  
Author(s):  
Murat Metehan Türkog̃lu ◽  
Melis Ulu Dog̃ru

We investigate cylindrically symmetric spacetimes in the context of [Formula: see text] gravity. We firstly attain conformal symmetry of the cylindrically symmetric spacetime. We obtain solutions to use features of the conformal symmetry, field equations and their solutions for cylindrically symmetric spacetime filled with various cosmic matters such as vacuum state, perfect fluid, anisotropic fluid, massive scalar field and their combinations. With the vacuum state solutions, we show that source of the spacetime curvature is considered as Casimir effect. Casimir force for given spacetime is found using Wald’s axiomatic analysis. We expose that the Casimir force for Boulware, Hartle–Hawking and Unruh vacuum states could have attractive, repulsive and ineffective features. In the perfect fluid state, we show that matter form of the perfect fluid in given spacetime must only be dark energy. Also, we offer that potential of massive and massless scalar field are developed as an exact solution from the modified field equations. All solutions of field equations for vacuum case, perfect fluid and scalar field give a special [Formula: see text] function convenient to [Formula: see text]-CDM model. In addition to these solutions, we introduce conformal cylindrical symmetric solutions in the cases of different [Formula: see text] models. Finally, geometrical and physical results of the solutions are discussed.


2000 ◽  
Vol 09 (05) ◽  
pp. 531-541 ◽  
Author(s):  
PEDRO F. GONZÁLEZ-DÍAZ

A link between the possibility of extending a geodesically incomplete kinked spacetime to a spacetime which is geodesically complete and the energy conditions is discussed for the case of a cylindrically-symmetric spacetime kink. It is concluded that neither the strong nor the weak energy condition can be satisfied in the four-dimensional example, though the latter condition may survive on the transversal sections of such a spacetime. It is also shown that the matter which propagates quantum-mechanically in a kinked spacetime can always be trapped by closed timelike curves, but signaling connections between that matter and any possible observer can only be made of totally incoherent radiation, so preventing observation of causality violation.


Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Ubiratan Cardinalli Adler ◽  
Maristela Schiabel Adler ◽  
Livia Mitchiguian Hotta ◽  
Ana Elisa Madureira Padula ◽  
Amarilys de Toledo Cesar ◽  
...  

Abstract Objectives To investigate the effectiveness and safety of homeopathic medicine Natrum muriaticum (LM2) for mild cases of COVID-19 in Primary Health Care. Trial design A randomized, two-armed (1:1), parallel, placebo-controlled, double-blind, clinical trial is being performed to test the following hypotheses: H0: homeopathic medicines = placebo (null hypothesis) vs. H1: homeopathic medicines ≠ placebo (alternative hypothesis) for mild cases of COVID-19 in Primary Care. Participants Setting: Primary Care of São Carlos – São Paulo – Brazil. One hundred participants aged 18 years or older, with Influenza-like symptoms and a positive RT-PCR for SARS-CoV-2. Willingness to give informed consent and to comply with the study procedures is also required. Exclusion criterium: severe acute respiratory syndrome. Intervention and comparator Homeopathy: 1 globule of Natrum muriaticum LM2 diluted in 20 mL of alcohol 30% and dispensed in a 30 ml bottle. Placebo: 20 mL of alcohol 30% dispensed in a 30 ml bottle. Posology: one drop taken orally every 4 hours (6 doses/day) while there is fever, cough, tiredness, or pain (headache, sore throat, muscle aches, chest pain, etc.) followed by one drop every 6 hours (4 doses/day) until the fourteenth day of use. The bottle of study medication should be submitted to 10 vigorous shakes (succussions) before each dose. Posology may be changed by telemedicine, with no break in blinding. Study medication should be maintained during home isolation. According to the Primary Care protocol, the home isolation period lasts until the 10th day after the appearance of the first symptom, or up to 72 hours without symptoms. Main outcomes The primary endpoint will be time to recovery, defined as the number of days elapsed before all COVID-19 Influenza-like symptoms are recorded as mild or absent during home isolation period. Secondary measures are recovery time for each COVID-19 symptom; score of the scale created for the study (COVID-Simile Scale); medicines used during follow-up; number of days of follow-up; number of visits to emergency services; number of hospitalizations; other symptoms and Adverse Events during home isolation period. Randomisation The study Statistician generated a block randomization list, using a 1:1 ratio of the two groups (denoted as A and B) and a web-based tool (http://www.random.org/lists). Blinding (masking) The clinical investigators, the statistician, the Primary Care teams, the study collaborators, and the participants will remain blinded from the identity of the two treatment groups until the end of the study. Numbers to be randomised (sample size) One hundred participants are planned to be randomized (1:1) to placebo (50) or homeopathy (50). Trial Status Protocol version/date May 21, 2020. Recruitment is ongoing. First participant was recruited/included on June 29,2020. Due to recruitment adaptations to Primary Care changes, the authors anticipate the trial will finish recruiting on April 10, 2021. Trial registration COVID-Simile Study was registered at the University Hospital Medical Information Network (UMIN - https://www.umin.ac.jp/ctr/index.htm) on June 1st, 2020, and the trial start date was June 15, 2020. Unique ID: UMIN000040602. Full protocol The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.


Infection ◽  
2021 ◽  
Author(s):  
Ali Hamady ◽  
JinJu Lee ◽  
Zuzanna A. Loboda

Abstract Objectives The coronavirus disease 2019 (COVID-19), caused by the novel betacoronavirus severe acute respiratory syndrome 2 (SARS-CoV-2), was declared a pandemic in March 2020. Due to the continuing surge in incidence and mortality globally, determining whether protective, long-term immunity develops after initial infection or vaccination has become critical. Methods/Results In this narrative review, we evaluate the latest understanding of antibody-mediated immunity to SARS-CoV-2 and to other coronaviruses (SARS-CoV, Middle East respiratory syndrome coronavirus and the four endemic human coronaviruses) in order to predict the consequences of antibody waning on long-term immunity against SARS-CoV-2. We summarise their antibody dynamics, including the potential effects of cross-reactivity and antibody waning on vaccination and other public health strategies. At present, based on our comparison with other coronaviruses we estimate that natural antibody-mediated protection for SARS-CoV-2 is likely to last for 1–2 years and therefore, if vaccine-induced antibodies follow a similar course, booster doses may be required. However, other factors such as memory B- and T-cells and new viral strains will also affect the duration of both natural and vaccine-mediated immunity. Conclusion Overall, antibody titres required for protection are yet to be established and inaccuracies of serological methods may be affecting this. We expect that with standardisation of serological testing and studies with longer follow-up, the implications of antibody waning will become clearer.


Sign in / Sign up

Export Citation Format

Share Document